Charles River Labs Intl Stock
€177.85
Your prediction
Charles River Labs Intl Stock
Pros and Cons of Charles River Labs Intl in the next few years
Pros
Cons
Performance of Charles River Labs Intl vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Charles River Labs Intl | -0.500% | -2.589% | -16.589% | -8.121% | -16.080% | -52.961% | - |
Ironwood Pharmaceuticals | -1.320% | 1.339% | -23.697% | -45.629% | -55.490% | -58.727% | -45.550% |
Arrowhead Pharmaceuticals Inc. | -8.710% | 8.804% | 0.375% | -5.453% | -14.418% | -58.563% | -25.502% |
Iovance Biotherapeutics Inc. | -0.710% | -1.312% | 47.603% | 84.607% | 34.862% | -48.958% | -44.579% |
Comments
News
![Charles River Laboratories Announces Second-Quarter 2024 Results: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM3drRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2d12e73cbe17e88591f046adade2e976603e2e80/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/charles_river_logo.jpg?locale=us)
Charles River Laboratories Announces Second-Quarter 2024 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2024. For the quarter, revenue was $1.03 billion, a decrease of 3.2% from $1.06
![Charles River Collaborates with Patient Advocacy Group, FOXG1 Research Foundation to Advance Rare Disease Gene Therapy Development: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM3drRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2d12e73cbe17e88591f046adade2e976603e2e80/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/charles_river_logo.jpg?locale=us)
Charles River Collaborates with Patient Advocacy Group, FOXG1 Research Foundation to Advance Rare Disease Gene Therapy Development
Charles River Laboratories International, Inc. (NYSE: CRL) announced today a collaboration with the FOXG1 Research Foundation (FRF) highlighting the patient advocacy group’s model to independently
![Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM3drRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2d12e73cbe17e88591f046adade2e976603e2e80/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/charles_river_logo.jpg?locale=us)
Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery
Charles River Laboratories International, Inc. (NYSE: CRL) and Autobahn Labs, a Samsara BioCapital-backed virtual accelerator for academic biotech, today announced a collaborative relationship that